Old Web
English
Sign In
Acemap
>
authorDetail
>
Jennifer Harbison
Jennifer Harbison
Chronic lymphocytic leukemia
Medicine
Immunology
Alemtuzumab
Molecular biology
3
Papers
410
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
with p53 mutations and deletions Alemtuzumab is an effective therapy for chronic lymphocytic leukemia
2013
M. R. Grever
John C. Byrd
Mollie E. Moran
Margaret S. Lucas
Thomas S. Lin
Marcy L. Hackbarth
John Proffitt
David M. Lucas
Gerard Lozanski
Nyla A. Heerema
Ian W. Flinn
Lisa L. Smith
Jennifer Harbison
Jennifer Webb
Show All
Source
Cite
Save
Citations (0)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
2004
Blood
Gerard Lozanski
Nyla A. Heerema
Ian W. Flinn
Lisa L. Smith
Jennifer Harbison
Jennifer Webb
Mollie E. Moran
Margaret Lucas
Thomas S. Lin
Marcy L. Hackbarth
Proffitt J
David M. Lucas
Michael R. Grever
John C. Byrd
Show All
Source
Cite
Save
Citations (408)
Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used.
2004
Blood
David M. Lucas
Gordon W. Dewald
Donna Neuberg
John C. Byrd
Gerard Lozanski
Jennifer Harbison
Kammy D. Cunningham
Ian W. Flinn
Martin S. Tallman
Michael R. Grever
Show All
Source
Cite
Save
Citations (2)
1